Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | XPO1 | O14980 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710354 | 0.84 | AKR1C3 (0.59) | CYP19A1ALOX5AKR1C3AKR1C2ABCB1 | |
| SCHEMBL19237501 | 0.81 | GABRA1 (0.52) | ALOX5PTPN1PPARGALDH1A1CYP3A4 | |
| SCHEMBL23027375 | 0.79 | CYP19A1 (0.47) | CYP19A1ALOX5PTGESNFKB1STAT3 | |
| SCHEMBL16710353 | 0.79 | HTT (0.57) | AKR1C3PTPN1PTGS2ALDH1A1CYP3A4 | |
| SCHEMBL18123531 | 0.79 | CYP19A1 (0.47) | CYP19A1ALOX5PTGESNFKB1STAT3 | |
| SCHEMBL6406971 | 0.78 | PDE4A (0.46) | PPARGPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22888403 | 0.78 | HTT (0.38) | CYP19A1AKR1C3AKR1C2PTPN1PTGS2 | |
| SCHEMBL8390906 | 0.76 | HDAC4 (0.44) | PPARGALDH1A1TACR1 | |
| SCHEMBL9886091 | 0.76 | TAAR1 (0.49) | ALDH1A1TACR1 | |
| SCHEMBL3303362 | 0.75 | CYP19A1 (0.56) | CYP19A1ALOX5PTGESNFKB1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2015070238-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | CYP19A1 567/4885ALOX5 4762/4885PTGES 2672/4885 |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | CYP19A1 567/4885ALOX5 4762/4885PTGES 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.